NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström ...

Transgenic animals continue to play an essential role in many aspects of zebrafish research, including the development of disease models. The most widely used system for zebrafish transgenesis is the ...

Angelman syndrome adalah kelainan genetik yang membuat anak memiliki karakteristik unik. Ketahui ciri-ciri dan perawatannya!

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

This approach effectively reduced side reactions caused by the broad substrate spectrum of 4-coumarate: CoA ligase and improved the efficiency of metabolic flux toward the target product. Based on ...

A groundbreaking study led by Li Yi, professor at the School of Life Sciences, was published in Nature on March 12, titled “Perception of viral infections and initiation of antiviral defence in rice”, ...

Redmile Group holds 4,193K shares representing 5.52% ownership ... Leveraging Nurix’s extensive expertise in E3 ligases ...

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

(Plexium), a leading next-generation targeted protein degradation company, today announced that initial Phase 1 clinical results with PLX-4545, a selective IKZF2 molecular glue degrader, and ...